文献速递白血病

脂质组学重编程将VEGF依赖的中枢神经系统适应与急性淋巴细胞白血病的铁死亡敏感性联系起来

Lipidomic reprogramming links VEGF-dependent CNS adaptation to ferroptosis sensitivity in acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2026-10-15

本研究基于NOD/SCID/huALL模型,探讨VEGF/VEGFR2在急性淋巴细胞白血病中枢神经系统浸润与生存中的作用。贝伐珠单抗主要减少已建立的中枢神经系统白血病而对浸润影响较小,索拉非尼可减少中枢神经系统白血病并诱导脂质过氧化和铁死亡;中枢来源白血病细胞脂质组学显示过氧化性增强与铁死亡易感性增加相关。

要点

  • VEGF主要支持中枢神经系统白血病细胞存活而非介导跨内皮迁移。
  • 索拉非尼在中枢神经系统微环境中高效减少白血病并诱导铁死亡。
  • 中枢白血病细胞脂质组学重编程增加过氧化性及铁死亡易感性。

核心结论

  • VEGF信号支持中枢神经系统白血病持续存在,脂质组学重编程产生高过氧化状态并增加铁死亡易感性。
  • 抑制VEGF信号同时诱导铁死亡可能成为中枢神经系统急性淋巴细胞白血病的治疗策略。

研究设计与样本

  • 研究使用NOD/SCID/huALL异种移植模型,可在中枢神经系统播散前后进行时间界定干预。
  • 体外评估跨内皮迁移,体内使用贝伐珠单抗和索拉非尼处理已建立的中枢神经系统白血病。

主要发现

  • 贝伐珠单抗持续减少已建立的中枢神经系统白血病,但对中枢神经系统进入仅有轻微影响。
  • 小鼠Vegfr2基因缺失或药理抑制均未损害体外跨内皮迁移。
  • 索拉非尼在该微环境中减少中枢神经系统白血病疗效最高,体外降低跨内皮迁移并诱导ALL细胞脂质过氧化伴铁死亡诱导。
  • 中枢来源ALL细胞脂质组学显示过氧化性增强,与铁死亡易感性增加相关。

临床怎么用

  • VEGF靶向治疗可能主要作用于已在中枢神经系统定植的白血病细胞而非预防浸润。
  • 索拉非尼在中枢神经系统白血病中显示高效,支持其在该场景的转化评估。
  • 联合抑制VEGF信号与诱导铁死亡可能是中枢神经系统ALL的潜在治疗方向。

局限性

  • 研究基于NOD/SCID/huALL异种移植模型,人体临床适用性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL) remains a major cause of treatment failure, underlying molecular mechanisms are not fully understood. Based on previous work implicating vascular endothelial growth factor A (VEGF), we dissected its contribution to VEGF receptor 2 (VEGFR2)-mediated CNS entry versus niche-dependent survival and evaluated VEGF-targeted strategies in translational xenograft models. Using the NOD/SCID/huALL model enabling temporally defined intervention before and after CNS dissemination, bevacizumab consistently reduced established CNS ALL but had only minor effects on CNS entry, indicating a predominant contribution of VEGF in CNS ALL survival. Consistently, neither genetic depletion nor pharmacologic inhibition of murine Vegfr2 impaired transendothelial migration (TEM) in vitro. To further substantiate the role of VEGF in CNS ALL, manifest disease was treated in vivo with the multi-kinase inhibitor Sorafenib that was previously shown effective in refractory CNS leukemia patients. Sorafenib reduced CNS ALL with the highest efficacy in this compartment. In vitro, Sorafenib decreased TEM but also induced lipid peroxidation in ALL cells accompanied by ferroptosis induction. Importantly, lipidomic profiling of CNS-derived ALL cells revealed enhanced peroxidizability linked to increased ferroptosis susceptibility, providing a mechanistic link for lipid peroxidation-driven cell death in the CNS. Collectively, our findings identify VEGF signaling and lipidomic remodeling as complementary mechanisms of CNS adaptation in ALL. While VEGF supports CNS persistence, lipidomic remodeling generates a highly peroxidizable state associated with increased ferroptosis susceptibility. These findings suggest that inhibiting VEGF signaling and simultaneously inducing ferroptosis may represent a therapeutic strategy for CNS ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Muench V, Koehler R, Abaei A, et al. Lipidomic reprogramming links VEGF-dependent CNS adaptation to ferroptosis sensitivity in acute lymphoblastic leukemia. Blood Adv. 2026. PMID: 42879737. doi:10.1182/bloodadvances.2026020816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。